Sandu Pharmaceuticals Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524703
₹36.20
Sept. 30, 2026 · BSE · bse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #160 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

CompanyMarket cap (₹ Cr)PE (TTM)ROE1Y returnDiv. yieldQualityValuationMomentum
Sun Pharmaceutical Industries Limited 435,863 146.5 13.7% 11.0% — 72 8 30
Divi's Laboratories Limited 246,660 83.9 15.3% 62.7% 0.32% 70 4 51
Torrent Pharmaceuticals Limited 162,454 78.2 12.2% 34.6% 0.79% 56 0 31
Zydus Lifesciences Limited 115,910 33.3 17.3% 17.2% 0.09% 74 24 84
Cipla Limited 108,736 35.4 11.2% -11.0% 0.97% 73 29 62
Laurus Labs Limited 106,969 122.5 17.1% 127.1% — 78 24 53
Mankind Pharma Limited 103,406 47.4 11.7% 2.6% — 68 12 86
Dr. Reddy's Laboratories Limited 102,916 154.7 10.9% -0.9% — 62 33 71
Sandu Pharmaceuticals Ltd. (this stock) 35 18.5 3.3% -35.8% — 59 88 45

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value
₹29 Cr
EV / EBITDA
8.5x
EV / Sales
0.42x
Market cap / Sales
0.50x
Earnings yield
5.41%

Quarterly Financials

↓ Negative
Quarterly Revenue

Jun 2026 quarterly revenue is Rs 16 Cr, down 1.9% YoY.

Period endRevenue (₹ Cr)PBT (₹ Cr)Net profit (₹ Cr)Basic EPS
June 30, 2026 16 0 — ₹0.3700
March 31, 2026 17 1 0 ₹0.0400
Dec. 31, 2025 19 1 — ₹1.0100
Sept. 30, 2025 18 1 — ₹0.5400
June 30, 2025 17 0 — ₹0.2300
March 31, 2025 14 0 0 ₹0.3400
Dec. 31, 2024 18 1 1 ₹0.5700
Sept. 30, 2024 18 1 0 ₹0.5200
June 30, 2024 17 0 0 ₹0.1700
March 31, 2024 16 1 1 ₹0.5000
Dec. 31, 2023 17 0 0 ₹0.2100
Sept. 30, 2023 17 1 1 ₹0.5700
June 30, 2023 18 0 0 ₹0.1100

Quarterly income statement (standalone, ₹ Cr)

IndicatorJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23
Total income (before exceptional items)16171918171418181716171718
Operating revenue16171918171418181716171718
Other income0000000000000
Operating expenses16161817161417171715171617
Operating profit1111101101110
Operating profit margin3.3%3.4%5.5%4.9%3.1%3.2%5.4%5.2%2.4%3.9%2.9%5.0%2.0%
Depreciation0000000000000
Interest0000000000000
Exceptional items, gain / (loss)—————————————
Profit before tax0111001101010
Tax01-00000000000
Net profit—0———01001010
EPS0.370.041.010.540.230.340.570.520.170.500.210.570.11
Net profit (TTM)—————22121111
EPS (TTM)1.961.822.121.681.661.601.761.401.451.391.161.471.54

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

IndicatorCAGR 3YCAGR 5YMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 19Mar 18Mar 17
Total income (before exceptional items) 2.3% 3.6% 70†67†68†66†66†59†50†53†45†
Operating revenue 2.3% 3.5% 70†67†67†65†66†59†49†53†45†
Other income — — 0†0†0†0†0†0†1†0†0†
Operating expenses — — 67†64†65†63†63†57†47†51†41†
Operating profit 6.4% 6.2% 3†3†2†2†3†2†2†2†4†
Operating profit margin — — 4.3%†4.1%†3.4%†3.8%†4.4%†3.8%†4.2%†4.6%†8.6%†
Depreciation — — 1†1†1†1†1†1†1†1†1†
Interest — — 0†0†0†0†0†0†1†1†1†
Exceptional items, gain / (loss) — — 0†0†0†0†0†0†0†0†0†
Profit before tax 6.1% 9.6% 3†2†2†2†2†2†1†1†1†
Tax — — 1†1†1†1†1†0†0†——
Net profit — — —2†1†2†2†1†1†0†0†
EPS 4.0% 1.7% 1.82†1.60†1.39†1.62†—1.67†———

† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

RatioMar 26Mar 25Mar 24Mar 23Mar 22Mar 21Mar 19Mar 18Mar 17
Operating margin4.3%†4.1%†3.4%†3.8%†4.4%†3.8%†4.2%†4.6%†8.6%†
EBIT margin4.0%†3.4%†3.2%†3.5%†3.7%†3.2%†4.1%†3.7%†5.6%†
PBT margin3.8%†3.2%†3.1%†3.4%†3.5%†2.9%†2.1%†1.4%†2.2%†
Net margin—2.3%†2.2%†2.3%†2.4%†2.0%†1.3%†0.9%†1.1%†
Interest coverage24.69x†21.87x†33.82x†28.91x†22.07x†10.81x†2.01x†1.61x†1.67x†
Dividend payout—————————
Earnings retention—————————
Current ratio2.43x2.18x———————
Quick ratio1.42x1.01x———————
Debt to equity0.01x0.00x———————
Return on equity—3.7%†———————
Return on assets—2.8%†———————
Return on capital employed6.1%†5.2%†———————
Asset turnover1.25x†1.21x†———————

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year endedOperating (₹ Cr)Investing (₹ Cr)Financing (₹ Cr)Capex (₹ Cr)Free Cash Flow (₹ Cr)
March 31, 2026 6 -1 -1 1 5
March 31, 2025 1 -0 -0 1 0

Balance Sheet (standalone)

Year endedTotal Assets (₹ Cr)Total Equity (₹ Cr)Reserves (₹ Cr)Borrowings, Current (₹ Cr)Borrowings, Non-current (₹ Cr)Current Assets (₹ Cr)Current Liabilities (₹ Cr)Cash & Equivalents (₹ Cr)Net Block (₹ Cr)Inventory (₹ Cr)
March 31, 2026 56 44 34 0 0 25 10 6 9 10
March 31, 2025 56 42 32 0 0 26 12 1 8 14

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.